Protagonist Therapeutics/$PTGX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Protagonist Therapeutics
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
- Ticker
- $PTGX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 141
- Headquarters
- Newark, United States
- Website
- www.protagonist-inc.com
PTGX Metrics
BasicAdvanced
$9.1B
114.84
$1.22
1.79
-
Price and volume
Market cap
$9.1B
Beta
1.79
52-week high
$160.81
52-week low
$75.44
Average daily volume
732K
Financial strength
Current ratio
21.709
Quick ratio
21.576
Long term debt to equity
0.008
Total debt to equity
0.011
Profitability
EBITDA (TTM)
59.883
Gross margin (TTM)
100.00%
Net profit margin (TTM)
29.40%
Operating margin (TTM)
20.69%
Effective tax rate (TTM)
1.69%
Revenue per employee (TTM)
$2,000,000
Management effectiveness
Return on assets (TTM)
4.55%
Return on equity (TTM)
10.98%
Valuation
Price to earnings (TTM)
114.838
Price to revenue (TTM)
32.182
Price to book
10.78
Price to tangible book (TTM)
10.78
Price to free cash flow (TTM)
69.497
Free cash flow yield (TTM)
1.44%
Free cash flow per share (TTM)
2.018
Growth
Revenue change (TTM)
34.81%
Earnings per share change (TTM)
51.80%
3-year earnings per share growth (CAGR)
-23.00%
10-year earnings per share growth (CAGR)
-35.13%
What the Analysts think about PTGX
Analyst ratings (Buy, Hold, Sell) for Protagonist Therapeutics stock.
Analyst projections of the future price of Protagonist Therapeutics stock.
Bulls say / Bears say
Icotrokinra has moved from pipeline promise to an approved product in the US and Europe, and J&J reported that psoriasis clearance remained strong through two years in a Phase 3 study. Durable results could support broader use of this first-in-class oral IL-23 treatment. (Johnson & Johnson)
The FDA approved rusfertide, branded MIMRYLO, for polycythaemia vera, giving Protagonist a second approved medicine in 2026. It offers a new treatment option for patients who have relied on regular bloodletting to manage the condition. (Reuters)
Both products depend on partners to run their commercial launches: J&J holds ICOTYDE’s worldwide development and commercial rights, while Takeda assumed sole operational responsibility for rusfertide. Protagonist has limited direct control over how quickly the products gain market share. (SEC)
MIMRYLO can bring a meaningful treatment burden: injection-site reactions occurred in 56% of trial patients and anaemia in 16%, and its label calls for monitoring for rising platelet counts. These issues could weigh on patient acceptance and prescribing. (Nasdaq)
The next growth drivers beyond partnered medicines remain early-stage: PN-881 was expected to enter a Phase 2 psoriasis study in early 2027, while obesity candidates were still in early development. Protagonist also expected R&D costs to rise significantly in the second half of 2026, increasing spend before these programmes prove their value. (Nasdaq, Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 17 Oct 2026.
PTGX Financial Performance
Revenues and expenses
PTGX Earnings Performance
Company profitability
Upcoming events
No upcoming events
PTGX News
AllArticlesVideos
Protagonist Therapeutics Announces $300 Million Share Repurchase Program
Accesswire2 months ago
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026
Accesswire2 months ago
Protagonist Wins FDA Approval for MIMRYLO in Rare Blood Cancer Treatment
MarketBeat2 months ago
Funds containing PTGX
AllUSDEURGBP
Fund name | Fund size | $PTGX weighting |
|---|---|---|
iShares Ageing Population$AGED | $953M | 0.64% |
iShares Ageing Population£AGES | $953M | 0.64% |
iShares Ageing Population€AGED | $903M | 0.64% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.58% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.58% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.